Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,582 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Tremelimumab, Durvalumab, Prevnar-13, Melphalan
Drug · Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Completed Not applicable Interventional Results available

Neural-net Artificial Pancreas (NAP)

NCT05876273
Conditions
Type1 Diabetes
Interventions
Neural-net Artificial Pancreas, University of Virginia Model Predictive Control
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions
CNP-103, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Completed Phase 1 Interventional Results available

Hyaluronidase Effect on Infusion Set Life

NCT02199028
Conditions
Type 1 Diabetes Mellitus
Interventions
Hyaluronidase, Control
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Type 1 Diabetes, Hypoglycemia Unawareness
Interventions
somatostatin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Diabetes Mellitus, Type 1
Interventions
hOKT3gamma1(Ala-Ala)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Conditions
Type 1 Diabetes, Pregnancy
Interventions
Automated Insulin Delivery
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Santa Barbara, California • Rochester, Minnesota • New York, New York
Conditions
Diabetes Mellitus, Type I
Interventions
Dexcom G4 or G5 Platinum CGM system, Dexcom G4 or G5 Platinum CGM system with Share
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Pancreatic Polypeptide (PP)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Withdrawn Not applicable Interventional Accepts healthy volunteers

Milk as Treatment for Hypoglycemia

NCT00643110
Conditions
Type 1 Diabetes
Interventions
D50 glucose
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Type1diabetes
Interventions
Quick Bolus, Standard Bolus
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Escondido, California
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Diabetes Mellitus, Type I
Interventions
blood draw or cheek swab
Other
Lead sponsor
GentiBio, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
San Francisco, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Conditions
Type 1 Diabetes Mellitus
Interventions
180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 35 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
Conditions
Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes, Covid19
Interventions
Bacillus Calmette-Guérin, Saline injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

NCT03107208
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Interventions
Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Type 1 Diabetes
Interventions
InPen®
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Type 1 Diabetes Mellitus
Interventions
GBP CGM
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Malignant Melanoma
Interventions
Tebentafusp (IMCgp100)
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more